Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 3/20 | 0.41 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007735 | 0.84 | CES2 (0.53) | TRPM8MTOR | |
| SCHEMBL14784157 | 0.81 | TRPM8 (0.56) | TRPM8RELA | |
| SCHEMBL29188757 | 0.80 | SLC6A4 (0.49) | ESR2DCLRE1BPTGER2TAAR1 | |
| SCHEMBL14783967 | 0.77 | ESR2 (0.50) | TRPM8ESR2MAP4K4DCLRE1BTAAR1 | |
| SCHEMBL29554674 | 0.76 | PKM (0.45) | — | |
| SCHEMBL12093236 | 0.76 | MLYCD (0.39) | TRPM8MTOR | |
| SCHEMBL19285067 | 0.76 | PKM (0.45) | — | |
| SCHEMBL12345357 | 0.76 | CA12 (0.42) | TRPM8ESR2MTOR | |
| SCHEMBL29363677 | 0.76 | DCLRE1B (0.60) | ESR2DCLRE1B | |
| SCHEMBL2160051 | 0.76 | DCLRE1B (0.60) | ESR2DCLRE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755944-B1 | BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-06-14 | — | — | EP | disclosed |
| EP-2755944-B1 | BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624159-B2 | Aniline derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2017-04-18 | — | — | US | disclosed |
| US-9624159-B2 | Aniline derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2017-04-18 | — | — | US | disclosed |
| US-9624159-B2 | Aniline derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2017-04-18 | — | — | US | disclosed |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2016-07-14 | — | — | US | disclosed |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2016-07-14 | — | — | US | disclosed |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2016-07-14 | — | — | US | disclosed |
| US-9249085-B2 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS (FR) | 2016-02-02 | — | — | US | disclosed |
| US-9249085-B2 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS (FR) | 2016-02-02 | — | — | US | disclosed |
| US-9249085-B2 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS (FR) | 2016-02-02 | — | — | US | disclosed |
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2014-11-27 | — | — | US | disclosed |
| EP-2755944-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037705-A9 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013037705-A9 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CYP11B1, CYP11B2, ARG2 | TRPM8 2834/4885ESR2 1310/4885MAP4K4 4023/4885 |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CYP11B1, ARG2, CYP11B2 | TRPM8 2901/4885ESR2 1213/4885MAP4K4 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.